Markers of hypercoagulability in CAD patients. Effects of single aspirin and clopidogrel treatment

Thrombosis Journal

Volumn 10, Issue , 2012, Pages

  Bratseth, Vibeke ^a   Pettersen, Alf Åge ^a,b   Opstad, Trine B ^a,b   Arnesen, Harald ^a,b,c   Seljeflot, Ingebjørg ^a,b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Antiplatelet treatment; Aspirin; Clopidogrel; Coronary artery disease; Endogenous thrombin potentiale; Hypercoagulability; Prothrombotic markers; The CAT assay; Thrombin generation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CARDIOVASCULAR RISK; CINEANGIOCARDIOGRAPHY; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; EX VIVO STUDY; FEMALE; HUMAN; HYPERCOAGULABILITY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; SMOKING; THROMBIN TIME; TREATMENT DURATION; TREATMENT RESPONSE; VENOUS BLOOD;

EID: 84864796614     PISSN: None     EISSN: 14779560     Source Type: Journal    
DOI: 10.1186/1477-9560-10-12     Document Type: Article

References (50)

1. World Health Organization Diabetes 2009, http://www.whoint/mediacentre/factsheets/fs312/en/, World Health Organization.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143. 10.1161/hc0902.104353, 11877368.
3. Robbie L, Libby P. Inflammation and atherothrombosis. Ann N Y Acad Sci 2001, 947:167-179.
4. Broze GJ. Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinolysis 1995, 6(Suppl 1):S7-S13.
5. Rapaport SI, Rao LV. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992, 12(10):1111-1121. 10.1161/01.ATV.12.10.1111, 1390583.
6. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006, 208(3):327-339. 10.1002/path.1871, 16261634.
7. Hemker HC, Al DR, de Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006, 96(5):553-561.
8. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100(8):793-798. 10.1161/01.CIR.100.8.793, 10458713.
9. Solheim S, Pettersen AA, Arnesen H, Seljeflot I. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary heart disease. Thromb Haemost 2006, 96(5):660-664.
10. Szczeklik A, Krzanowski M, Gora P, Radwan J. Antiplatelet drugs and generation of thrombin in clotting blood. Blood 1992, 80(8):2006-2011.
11. Pettersen A-Å R SIAMAH Residual platelet reactivity on single aspirin treatment as related to clinical end points in patients with stable coronary artery disease. Results from the ASCET trial. 2012. Am Heart Assoc 2012, Ref Type: Generic, Pettersen A-Å R SIAMAH.
12. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 2005, 4(4):198-203. 10.1097/00132577-200512000-00018, 18340209.
13. Hemker HC, Giesen P, Al DR, Regnault V, De Smedt E, Wagenvoord R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003, 33(1):4-15. 10.1159/000071636, 12853707.
14. Opstad TB, Pettersen AA, Weiss T, Arnesen H, Seljeflot I. Gender differences of polymorphisms in the TF and TFPI genes, as related to phenotypes in patients with coronary heart disease and type-2 diabetes. Thromb J 2010, 8:7. 10.1186/1477-9560-8-7, 2882354, 20444258.
15. Cadroy Y, Pierrejean D, Fontan B, Sie P, Boneu B. Influence of aging on the activity of the hemostatic system: prothrombin fragment 1 + 2, thrombin-antithrombin III complexes and D-dimers in 80 healthy subjects with age ranging from 20 to 94 years. Nouv Rev Fr Hematol 1992, 34(1):43-46.
16. Lowe GD, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997, 97(4):775-784. 10.1046/j.1365-2141.1997.1222936.x, 9217176.
17. Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006, 95(5):772-775.
18. van Hylckama V, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007, 138(6):769-774. 10.1111/j.1365-2141.2007.06738.x, 17760809.
19. Ossei-Gerning N, Wilson IJ, Grant PJ. Sex differences in coagulation and fibrinolysis in subjects with coronary artery disease. Thromb Haemost 1998, 79(4):736-740.
20. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993, 98(1):83-90. 10.1016/0021-9150(93)90225-J, 8457253.
21. Caponnetto P, Russo C, Di MA, Morjaria JB, Barton S, Guarino F, et al. Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest 2011, 41(6):616-626. 10.1111/j.1365-2362.2010.02449.x, 21198559.
22. Cacciola RR, Guarino F, Polosa R. Relevance of endothelial-haemostatic dysfunction in cigarette smoking. Curr Med Chem 2007, 14(17):1887-1892. 10.2174/092986707781058832, 17627524.
23. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 1994, 128(1):7-11. 10.1016/0002-8703(94)90003-5, 8017287.
24. Celi A, Cianchetti S, Dell'Omo G, Pedrinelli R. Angiotensin II, tissue factor and the thrombotic paradox of hypertension. Expert Rev Cardiovasc Ther 2010, 8(12):1723-1729. 10.1586/erc.10.161, 21108554.
25. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007, 262(2):157-172. 10.1111/j.1365-2796.2007.01824.x, 17645584.
26. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension?. Atherosclerosis 2008, 196(1):1-8. 10.1016/j.atherosclerosis.2007.06.006, 2742669, 17662294.
27. Vijayaraghavan K, Deedwania P. Renin-angiotensin-aldosterone blockade for cardiovascular disease prevention. Cardiol Clin 2011, 29(1):137-156. 10.1016/j.ccl.2010.11.003, 21257105.
28. Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000, 45:419-429.
29. Celi A, Del FA, Cianchetti S, Pedrinelli R. Tissue factor modulation by Angiotensin II: a clue to a better understanding of the cardiovascular effects of renin-angiotensin system blockade?. Endocr Metab Immune Disord Drug Targets 2008, 8(4):308-313. 10.2174/187153008786848259, 19075785.
30. Vaughan DE. The renin-angiotensin system and fibrinolysis. Am J Cardiol 1997, 79(5A):12-16.
31. Sechi LA, Novello M, Colussi G, Di FA, Chiuch A, Nadalini E, et al. Relationship of plasma renin with a prothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008, 21(12):1347-1353. 10.1038/ajh.2008.293, 18948960.
32. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329-1339. CAPRIE Steering Committee.
33. Beguin S, Keularts I. On the coagulation of platelet-rich plasma. Physiological mechanism and pharmacological consequences. Haemostasis 1999, 29(1):50-57.
34. Bauer KA. Laboratory markers of coagulation activation. Arch Pathol Lab Med 1993, 117(1):71-77.
35. Brodin E, Seljeflot I, Arnesen H, Hurlen M, Appelbom H, Hansen JB. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res 2009, 123(4):573-579. 10.1016/j.thromres.2008.03.018, 18474393.
36. Kyrle PA, Westwick J, Scully MF, Kakkar VV, Lewis GP. Investigation of the interaction of blood platelets with the coagulation system at the site of plug formation in vivo in man-effect of low-dose aspirin. Thromb Haemost 1987, 57(1):62-66.
37. Undas A, Undas R, Musial J, Szczeklik A. A low dose of aspirin (75 mg/day) lowers thrombin generation to a similar extent as a high dose of aspirin (300 mg/day). Blood Coagul Fibrinolysis 2000, 11(3):231-234.
38. Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007, 109(6):2285-2292. 10.1182/blood-2006-01-010645, 1852201, 17148593.
39. Matetzky S, Tani S, Kangavari S, Dimayuga P, Yano J, Xu H, et al. Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 2000, 102(6):602-604. 10.1161/01.CIR.102.6.602, 10931797.
40. Osnes LT, Foss KB, Joo GB, Okkenhaug C, Westvik AB, Ovstebo R, et al. Acetylsalicylic acid and sodium salicylate inhibit LPS-induced NF-kappa B/c-Rel nuclear translocation, and synthesis of tissue factor (TF) and tumor necrosis factor alfa (TNF-alpha) in human monocytes. Thromb Haemost 1996, 76(6):970-976.
41. Dropinski J, Musial J, Jakiela B, Wegrzyn W, Sanak M, Szczeklik A. Anti-thrombotic action of clopidogrel and P1(A1/A2) polymorphism of beta3 integrin in patients with coronary artery disease not being treated with aspirin. Thromb Haemost 2005, 94(6):1300-1305.
42. Herault JP, Dol F, Gaich C, Bernat A, Herbert JM. Effect of clopidogrel on thrombin generation in platelet-rich plasma in the rat. Thromb Haemost 1999, 81(6):957-960.
43. Eikelboom JW, Weitz JI, Budaj A, Zhao F, Copland I, Maciejewski P, et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2002, 23(22):1771-1779. 10.1053/euhj.2000.3234, 12419297.
44. Kringen MK, Narum S, Lygren I, Seljeflot I, Sandset PM, Troseid AM, et al. Reduced platelet function and role of drugs in acute gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2011, 108(3):194-201. 10.1111/j.1742-7843.2010.00643.x, 21118353.
45. Undas A, Stepien E, Branicka A, Wolkow P, Zmudka K, Tracz W. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin. Kardiol Pol 2009, 67(6):591-598.
46. Leon C, Alex M, Klocke A, Morgenstern E, Moosbauer C, Eckly A, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood 2004, 103(2):594-600. 10.1182/blood-2003-05-1385, 12969982.
47. Rao AK, Vaidyula VR, Bagga S, Jalagadugula G, Gaughan J, Wilhite DB, et al. Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease. Thromb Haemost 2006, 96(6):738-743.
48. Parhami-Seren B, Butenas S, Krudysz-Amblo J, Mann KG. Immunologic quantitation of tissue factors. J Thromb Haemost 2006, 4(8):1747-1755. 10.1111/j.1538-7836.2006.02000.x, 16879217.
49. Morange PE, Renucci JF, Charles MA, Aillaud MF, Giraud F, Grimaux M, et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost 2001, 85(6):999-1003.
50. Winckers K, Siegerink B, Duckers C, Maurissen LF, Tans G, Castoldi E, et al. Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study. J Thromb Haemost 2011, 9(11):2243-2250. 10.1111/j.1538-7836.2011.04497.x, 21895962.